Glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide and dual GLP-1 and glucose-dependent insulinotropic polypeptide receptor agonists such as tirzepatide could curb both the health ...
However, to date, no clinical trial has specifically evaluated the efficacy of GLP-1 receptor agonists on morbidity and mortality in people with heart failure. Semaglutide was recently shown to ...
To the Editor: The distribution framework for glucagon-like peptide-1 (GLP-1) receptor agonists proposed by Emanuel et al. in their Perspective article (May 30 issue) 1 considers potential years ...